SAT0357

COMPLIANCE AND PERSISTENCE TO URATE LOWERING THERAPY FOR THE TREATMENT OF GOUT AND HYPERURICEMIA: A RETROSPECTIVE ANALYSIS OF MEDICATION PRESCRIPTION RECORDS

C.A. Janssen¹, M.A. Oude Voshaar¹, H.E. Vonkeman^{1,2}, M. Krol³, M.A. van de Laar^{1,2}. ¹Arthritis Center Twente, Department of Psychology, Health and Technology, University of Twente; ²Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede; ³Real World Evidence Solutions, IQVIA, Amsterdam, Netherlands

Background: Hyperuricemia is the predominant risk factor for gout, a common crystal-induced disease, manifested as an acute inflammatory arthritis. Urate lowering therapy (ULT) is an effective and recommended life-long treatment for lowering and managing serum urate levels in gout patients.¹ However, recurrent attacks of gouty arthritis are commonly observed in practice, even during long-term ULT.² This is often attributed to poor medication adherence and continuance.³ Gaining insight into the dispensing patterns and medication adherence of ULT, provides a reflection of the current gout care delivered by health professionals.

Objectives: To examine the levels of compliance and persistence to commonly prescribed ULT for the treatment of hyperuricemia and gout in the Netherlands.

Methods: Anonymous medication prescription records were obtained from IQVIA's longitudinal prescription database in The Netherlands, containing ULT dispensing data (allopurinol, febuxostat and benzbromarone) from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over a period of 12 consecutive months. Good compliance was defined as a PDC ≥ 0.80. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of >30 days. The association of PDC and persistence with age, gender and first prescriber were examined using beta regression- and cox-regression models, respectively.

Abstract SAT0357 – Table 1. Variables associated with PDC

	Univariate analyses			Multivariate analyses ¹		
	Gender	Age	Prescriber	Gender	Age	Prescriber
β-coefficient	-0.044*	0.011**	0.336**	-0.127**	0.012**	0.348**
SE	0.014	<0.000	0.015	0.014	<0.000	0.015
Pseudo R²	<0.000	0.011	0.011	0.024	0.024	0.024

¹ Model: PDC~gender+ age+prescriber. *p<0.01; **p<0.001; SE, standard error; PDC, proportion of days covered.

Abstract SAT0357 – Figure 1. Survival curves of persistence of ULT drugs one year after initiation of treatment.

Results: In total, 45 654 patients were identified meeting the enrollment criteria, of which 76.1% were male. The initial ULT drug prescribed most frequently among general practitioners and rheumatologists was allopurinol 100 mg, 75.9% and 72.1%, respectively. In total, 51.7% of the cases had good compliance after one year. The median time to discontinuation was 248 days, and after one year 42.7%

of the cases were still persistent. In general, men, older patients and patients whose first prescriber was a rheumatologist were more persistent, and had a higher PDC, although effect sizes were modest (table 1 and Abstract SAT0357 – figure 1).

Conclusions: Our results show that medication adherence to ULT after one year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence are warranted.

REFERENCES:

- [1] Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis* 2017;76:29–42.
- [2] Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? *Ann Rheum Dis* 2012;71:1765–70.
- [3] Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. *Patient Prefer Adherence* 2017;11:795–800.

Acknowledgements: This study was supported by Grünenthal B.V.

Disclosure of Interest: C. Janssen: None declared, M. Oude Voshaar: None declared, H. Vonkeman: None declared, M. Krol: None declared, M. van de Laar: Grant/research support from: Our department received an unrestricted education grant by Grünenthal B.V. to perform this study., Consultant for: MvdL received consultancy fees from Grünenthal B.V.

DOI: 10.1136/annrheumdis-2018-eular.3022

SAT0358

DIABETES AND GOUT: REAL-WORLD EVIDENCE EVALUATING PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE UTILISATION

D.C. Taylor¹, A.-C. Fu¹, R. Morlock². ¹Ironwood Pharmaceuticals, Inc., Cambridge; ²YourCareChoice, Ann Arbor, USA

Background: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and hyperuricemia/gout with clinical outcomes. This study examined variations in gout severity, management, and health care utilisation among gout patients with and without T2DM.

Methods: Data were assessed from a survey of US physicians and patient chart audits. Participating physicians managed the care of ≥50 patients with gout annually; chart audits were of their last 5 consecutive adult patients with confirmed gout. Gout severity was measured by physician global assessment, flares, organ/joint damage, and tophi. Treatment characteristics, presence of clinician-confirmed T2DM, and socio-demographics were identified. Descriptive and multivariate (stepwise logistic regression) statistics analysed the differences among gout patients with and without clinician-confirmed comorbid T2DM and assessed urate-lowering therapy (ULT) use and gout control.

Results: Overall, 1159 charts of patients with gout were abstracted (246 with T2DM, 913 without T2DM; 81% male; 71% Caucasian); the proportion of patients aged ≥61 with gout was greater for those with T2DM than without T2DM (69% vs 31%; p<0.01). Patients with gout and T2DM had longer mean duration of gout (63 vs 41 months), were more likely to have tophi (37% vs 20%), joint damage (24% vs 13%), and clinician-rated severe gout (27% vs 13%) than those without T2DM (all p<0.01). Patients with gout and T2DM were also more likely to receive ULT than those without T2DM (86% vs 71%; p<0.01), and among those patients with gout and T2DM receiving allopurinol, mean daily doses were not significantly different (321 mg vs 298 mg; p=0.17). Gout patients with T2DM were more likely to have additional comorbidities (cardiovascular disease, kidney disease, COPD, depression, diabetes, hyperlipidemia, hypertension, obesity, prostate problems [men]) and have chronic pain than those without T2DM (all p<0.05). On average, gout patients with T2DM vs. those without T2DM reported more office visits (4.1 vs 3.5), were more likely to have an emergency department visit (17% vs 9%) and were more likely to have a hospitalisation (5% vs 2%) (all p<0.01). In both groups, ULT use was associated with better gout control, but the specific factors predictive of ULT use and disease control varied between those with and without T2DM.

Conclusions: Gout patients with T2DM were more likely to have a greater impact on health system utilisation and spending, with additional comorbidities and more severe gout than those without T2DM. These data suggest that patients with gout and T2DM constitute a less healthy group in need of careful monitoring and more aggressive gout management.

Acknowledgements: This study was funded by Ironwood Pharmaceuticals.

Disclosure of Interest: D. Taylor Shareholder of: Ironwood Pharmaceuticals, Inc., Employee of: Ironwood Pharmaceuticals, Inc., A.-C. Fu Employee of: Ironwood Pharmaceuticals, Inc., R. Morlock Consultant for: Ironwood Pharmaceuticals, Inc.

DOI: 10.1136/annrheumdis-2018-eular.6701

SAT0359 EVOLUTION OF RENAL FUNCTION IN GOUT AFTER NORMALISATION OF SERUM URIC ACID LEVEL

E. Gazeix-Fontaine¹, A. Ostertag², H.-K. Ea¹, F. Lioté¹. ¹Rheumatology Department, ²INSERM UMR 1132 Bioscar, Centre Viggo Petersen, Hospital Lariboisière, Paris, France

Background: Chronic kidney disease (CKD) is one of the main causes of mortality in gout. In addition, hyperuricemia can contribute to the decrease of renal function.

Objectives: The aim of this study was to evaluate the evolution of renal function after reducing serum uric acid (sUA) level to therapeutic target in gout, and to identify the factors that might influence this evolution.

Methods: Patients with gout were followed at a single university-based hospital. They were free of urate lowering therapy (ULT) and had an estimated glomerular filtration rate (eGFR) higher than 15 ml/min. Renal function was measured at start of ULT and when sUA was reduced below 360 µmol/L (or 6.0 mg/dL). ULT was allopurinol or febuxostat at the choice of clinician.

Results: In this retrospective study, 63 patients (pts) were included with an initial mean sUA level of 541 µmol/L (±86). Overall 42 pts were treated with allopurinol and 21 with febuxostat for an average length of 278 days (±185). After ULT, mean eGFR differed significantly: +2.6 [IC95%: -0.279; 5.484; p=0.08], +3 [IC95%: 0.167; 5.794; p=0.04] and +2.7 [IC95%: 0.490; 4.960; p=0.02] ml/min/1.73 m² depending on the calculation method, Cockcroft-Gault (C-G), MDRD and CKD-EPI, respectively. eGFR improvement was statistically significant, p=0.04, 0.02 et 0.01, respectively. Initial eGFR >45 ml/min/1.73 m² was associated with a better outcome of eGFR expressed in percentage: +4.7% vs -7.3% (p=0.02), +6.3% vs -4.9% (p=NS), +6.2% vs -5.3% (p=0.03) according to the calculation method, C-G, MDRD and CKD-EPI, respectively. We also found a better evolution of renal function when patients were treated with allopurinol compared to febuxostat, but confounding bias might have occurred since their mean eGFR was also better. In contrast, neither sex, BMI, presence of hypertension nor diabetes showed any significant effect on eGFR improvement.

Conclusions: Renal function was significantly different after normalisation of sUA in gout patients. We observed an improvement of eGFR which is consistent with recent studies. Interestingly, when initial renal function was at CKD IIIa level or higher (eGFR >45 ml/min/1.73 m²), renal outcome was even better. It strengthens the rationale to treat high sUA as soon as possible.

Acknowledgements: Thanks to Frédéric Lioté^{1,2,3}, Hang-Korng Ea^{1,2,3} and Agnès Ostertag²

¹ Rheumatology Department and ² INSERM UMR 1132 Bioscar, Centre Viggo Petersen, (AP-HP) hospital Lariboisière; ³ Univ. Paris Diderot, USPC, Paris, France

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3773

SAT0360 A SUMMARY OF CLINICAL EVIDENCE FOR COMMONLY USED URICOSURICS FOR GOUT IN EUROPE

F. Perez-Ruiz¹, P. Kandaswamy², R. Karra Gurunath², H. Burton³, T. Jansen⁴. ¹Rheumatology Division, Hospital Universitario Cruces, Bilbao, Spain; ²Grunenthal GmbH, Aachen, Germany; ³DRG Abacus, Bicester, UK; ⁴Rheumatology, VieCuri MC, Venlo, Netherlands

Background: Uricosurics (benzbromarone, probenecid, or sulfinpyrazone) are recommended for second-line treatment of gout if treatment target cannot be achieved with allopurinol or if allopurinol cannot be tolerated. While some uricosurics have been available since the 1970s, only two head-to-head trials have been conducted, both of which compared benzbromarone with probenecid. A new uricosuric, lesinurad, has recently been developed, but also has no head-to-head data against current uricosurics. There is therefore a need to compare the efficacy of uricosurics relative to each other via network meta-analysis (NMA), which requires high-quality evidence from well conducted trials, and also for evidence-based recommendations.

Objectives: To identify and assess the quality of the randomised controlled trial (RCT) evidence for uricosurics currently licensed for the treatment of gout, and to assess the feasibility of developing an NMA based on these trials.

Methods: A systematic review was conducted to identify RCT evidence for uricosurics, followed by an assessment of the quality of the comparisons possible based on this evidence using the GRADE system. This assessment was then used in a feasibility assessment for NMA based on the comparability of the trials in terms of population, comparators, and outcomes.

Results: In total, 21 publications reporting on 13 unique studies were identified by the SR, two of which had no common comparator arm with other trials and were excluded from further assessment. Eleven studies were included in the quality assessment informing comparisons between treatments for two outcomes: proportion of patients achieving sUA <6 mg/dL (or 0.36 mmol/L) and change from baseline in sUA. Issues with two or more elements of the methodological quality of the studies were present in all comparisons other than lesinurad plus allopurinol vs placebo plus allopurinol, including open-label design, incomplete reporting and sparse data mainly of safety assessment, and inadequate randomisation. The outcomes assessed in these RCTs were generally comparable across trials, but follow-up time ranged from 1 week to a mean of 19.6 months and few trials reported data at the same endpoint. In addition, line of therapy was unclear/not reported in four trials, with uricosurics used in a first-line population in two trials. The final GRADE quality rating was 5 (high) for lesinurad plus allopurinol vs placebo plus allopurinol and -1 to 1 (very low) for all other comparisons (febuxostat plus lesinurad was not included in comparisons). Based on this assessment, it was concluded that a NMA or other statistical comparison is not possible because of substantial heterogeneity between trials for methodological quality, outcomes, and population.

Conclusions: The quality of the randomised controlled trial evidence supporting the use of uricosurics other than lesinurad for gout is poor, and there is substantial heterogeneity in reported follow-up times and study populations. It is therefore not possible to make valid comparisons between these treatments based on this data, which may have implications for decision-makers in assessments of future treatments for gout.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3026

SAT0361 TRABECULAR BONE SCORE IN OSTEOGENESIS IMPERFECTA. IS IT USEFUL?

H. Florez¹, A. Muxi², E. Gonzalez³, A. Monegal¹, N. Gualabens¹, P. Peris¹. ¹Metabolic Bone Diseases Unit, Department of Rheumatology; ²Department of Nuclear Medicine; ³Department of Immunology, HOSPITAL CLÍNIC, Barcelona, Spain

Background: The trabecular Bone Score (TBS) is a novel gray-level textural analysis measurement that can be applied to DXA images to estimate trabecular microarchitecture and has been shown to be related to direct measures of bone microarchitecture and fracture risk. Osteogenesis imperfecta (OI) is a congenital bone disease characterised by a low bone mineral density (BMD) and poor bone quality and strength. The usefulness of TBS in OI has been scarcely evaluated.

Objectives: To analyse the clinical usefulness of TBS determination in patients with OI and its relation with anthropometric and clinical features (especially concerning skeletal fractures and BMD results).

Methods: Twenty-four patients (18 F:6 M) with OI with a mean age of 38±15 years¹⁹⁻⁶³ attending a Metabolic Bone Disease Unit were included. The clinical reports of the patients were reviewed, with especial attention to the clinical features (weight, height and body mass index [BMI]), previous fractures, disease severity, associated mutations and treatments received. Lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD were measured using DXA equipment (Lunar) in all patients. TBS was analysed in LS, and the results were classified in three categories¹: TBS >1.310 (normal), TBS 1.230-1.310 (partially degraded microarchitecture), TBS <1.230 (degraded microarchitecture). TBS values were compared with a healthy control group of similar age and gender.

Results: 5/24 patients (21%) had a degraded microarchitecture, 4 (17%) a partially degraded microarchitecture and 15 (63%) normal TBS. All patients with TBS <1.230 were over 40 years old. 21/24 patients had a previous history of multiple fractures. Regarding BMD, 54% of the patients had osteoporosis, 42% osteopenia and one had normal values. Most patients had a mutation in the COL1A1 gene (63%). A correlation was observed between TBS and age (r=-0.5, p=0.006) and LS BMD (r=0.5, p=0.014), showing a trend to significance with BMI (r=-0.4, p=0.058). No significant differences were observed on comparing TBS in patients and controls (1.321 vs. 1.391, p=N.S.).

Conclusions: TBS measurement does not seem to be useful for evaluating bone strength in patients with OI. Despite most patients presenting a history of multiple fractures, only 21% showed degraded microarchitecture with TBS.

REFERENCE:

[1] McCloskey EV, Odén A, Harvey NC, et al. J Bone Miner Res 2016;31:940-8.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4883